China Approves Orforglipron, First Oral GLP-1 Weight-Loss Pill

Complete guide: GLP-1 drugs: a complete guide to semaglutide and beyond

The short version: on November 12, 2026, it was reported that China approved orforglipron, Eli Lilly's oral non-peptide GLP-1 receptor agonist, for weight management in adults with overweight or obesity. The news came from Lilly's Chinese unit and was carried by pharmaphorum and Reuters¹²³. It is the first GLP-1 pill approved for that use in China, the world's second-largest pharmaceutical market, where only injections were available before². This article is regulatory and scientific information for health professionals.

What was approved in China and what the sources say

According to pharmaphorum, Lilly's Chinese subsidiary says it is the first oral GLP-1 agonist approved in the country for weight management. The same outlet notes that orforglipron is sold as Foundayo in the US and UK, its first two markets¹. The FDA approved it on April 1, 2026 to reduce excess body weight and maintain weight reduction in adults with obesity, or with overweight and at least one weight-related comorbidity, alongside a reduced-calorie diet and more physical activity⁷.

Lilly filed with China's National Medical Products Administration (NMPA) at the end of 2025, for type 2 diabetes and obesity⁶. The type 2 diabetes application is still under review, according to pharmaphorum¹. A Lilly executive told Reuters in June that launch could come "anything from late 2026 to early 2027" through Alibaba and JD Health International⁵.

What is still unknown

The three reports of the approval agree on the core fact, but none gives the exact approval date, the Chinese brand name, the authorized dose or local clinical data¹²³. Lilly did not immediately comment on pricing or launch timing, and what appeared to be a promotion for the drug showed up on JD.com's app on Thursday³. The NMPA label will settle the exact indication.

In China, weight-loss drugs are self-funded: there is no public insurance coverage and almost no private coverage, and out-of-pocket sales are driven mainly by middle- and high-income urban residents¹.

The clinical evidence for orforglipron

In ATTAIN-1, a phase 3 trial of 3,127 adults with obesity and no diabetes, mean body-weight change at 72 weeks was -7.5% with 6 mg, -8.4% with 12 mg and -11.2% with 36 mg, versus -2.1% with placebo. Adverse events led to discontinuation in 5.3–10.3% of orforglipron patients and 2.7% on placebo, mostly mild-to-moderate gastrointestinal effects⁸.

ATTAIN-J, in 238 Japanese adults, is the closest East Asian data: at 72 weeks weight changed -5.9%, -8.7% and -7.9% with 6, 12 and 36 mg, versus -0.6% with placebo¹⁰. We did not find a published obesity trial in a Chinese population in open sources. Chinese sites did take part in ACHIEVE-3, an open-label 52-week type 2 diabetes study: orforglipron 36 mg lowered HbA1c by 1.91 points versus 1.47 with oral semaglutide 14 mg (difference -0.44; p<0.0001)¹¹.

Orforglipron versus oral semaglutide

In obesity, oral semaglutide 25 mg produced -13.6% body weight at 64 weeks versus -2.2% on placebo in OASIS 4, with gastrointestinal events in 74.0% versus 42.2%⁹. There is no head-to-head obesity trial. An adjusted indirect comparison by Novo Nordisk employees estimated 3.2 percentage points more weight loss with semaglutide 25 mg than orforglipron 36 mg, and more discontinuations with orforglipron¹². That analysis has a commercial interest and does not replace a direct trial.

Oral versus injectable: the adherence debate

Lilly argues that the route of administration is one of the factors affecting adherence in overweight and obesity¹. Real-world evidence is mixed and comes from type 2 diabetes with semaglutide, not orforglipron. At one Italian center (242 patients), 12-month persistence was 72.3% on the pill versus 92.4% on the weekly injection¹³. In a Japanese claims database with matched pairs, the injection carried higher odds of non-adherence (OR 1.39) and discontinuation (HR 1.45), although the pill was dropped more often early on¹⁴.

The practical point for clinicians: patient preference matters, but there are no orforglipron persistence data in obesity to settle the question.

What comes next in China

Novo Nordisk applied to sell oral Wegovy in China and the regulator accepted the application, Reuters reported on August 27⁴. Jiangsu Hengrui and Huadong Medicine have GLP-1 pills under review³. The pill will compete with Lilly's own weekly injection and with injections from Novo, Pfizer and Innovent Biologics². Injectable tirzepatide and semaglutide have been available in China since 2024¹. With self-pay patients, unannounced pricing and several rivals in review, orforglipron's launch will be the first real test of how much demand exists for an oral option.